P1731: IBRUTINIB PLUS RCHOP VERSUS RCHOP ONLY, IN YOUNG PATIENTS WITH ACTIVATED B CELL-LIKE DIFFUSE LARGE B-CELL LYMPHOMA (ABC-DLBCL): A COST EFFECTIVENESS ANALYSIS

Detalles Bibliográficos
Autores principales: Rho, H., Jeong, I. J.-H., Prica, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430548/
http://dx.doi.org/10.1097/01.HS9.0000849780.37760.ca
_version_ 1784779802174029824
author Rho, H.
Jeong, I. J.-H.
Prica, A.
author_facet Rho, H.
Jeong, I. J.-H.
Prica, A.
author_sort Rho, H.
collection PubMed
description
format Online
Article
Text
id pubmed-9430548
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94305482022-08-31 P1731: IBRUTINIB PLUS RCHOP VERSUS RCHOP ONLY, IN YOUNG PATIENTS WITH ACTIVATED B CELL-LIKE DIFFUSE LARGE B-CELL LYMPHOMA (ABC-DLBCL): A COST EFFECTIVENESS ANALYSIS Rho, H. Jeong, I. J.-H. Prica, A. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430548/ http://dx.doi.org/10.1097/01.HS9.0000849780.37760.ca Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Rho, H.
Jeong, I. J.-H.
Prica, A.
P1731: IBRUTINIB PLUS RCHOP VERSUS RCHOP ONLY, IN YOUNG PATIENTS WITH ACTIVATED B CELL-LIKE DIFFUSE LARGE B-CELL LYMPHOMA (ABC-DLBCL): A COST EFFECTIVENESS ANALYSIS
title P1731: IBRUTINIB PLUS RCHOP VERSUS RCHOP ONLY, IN YOUNG PATIENTS WITH ACTIVATED B CELL-LIKE DIFFUSE LARGE B-CELL LYMPHOMA (ABC-DLBCL): A COST EFFECTIVENESS ANALYSIS
title_full P1731: IBRUTINIB PLUS RCHOP VERSUS RCHOP ONLY, IN YOUNG PATIENTS WITH ACTIVATED B CELL-LIKE DIFFUSE LARGE B-CELL LYMPHOMA (ABC-DLBCL): A COST EFFECTIVENESS ANALYSIS
title_fullStr P1731: IBRUTINIB PLUS RCHOP VERSUS RCHOP ONLY, IN YOUNG PATIENTS WITH ACTIVATED B CELL-LIKE DIFFUSE LARGE B-CELL LYMPHOMA (ABC-DLBCL): A COST EFFECTIVENESS ANALYSIS
title_full_unstemmed P1731: IBRUTINIB PLUS RCHOP VERSUS RCHOP ONLY, IN YOUNG PATIENTS WITH ACTIVATED B CELL-LIKE DIFFUSE LARGE B-CELL LYMPHOMA (ABC-DLBCL): A COST EFFECTIVENESS ANALYSIS
title_short P1731: IBRUTINIB PLUS RCHOP VERSUS RCHOP ONLY, IN YOUNG PATIENTS WITH ACTIVATED B CELL-LIKE DIFFUSE LARGE B-CELL LYMPHOMA (ABC-DLBCL): A COST EFFECTIVENESS ANALYSIS
title_sort p1731: ibrutinib plus rchop versus rchop only, in young patients with activated b cell-like diffuse large b-cell lymphoma (abc-dlbcl): a cost effectiveness analysis
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430548/
http://dx.doi.org/10.1097/01.HS9.0000849780.37760.ca
work_keys_str_mv AT rhoh p1731ibrutinibplusrchopversusrchoponlyinyoungpatientswithactivatedbcelllikediffuselargebcelllymphomaabcdlbclacosteffectivenessanalysis
AT jeongijh p1731ibrutinibplusrchopversusrchoponlyinyoungpatientswithactivatedbcelllikediffuselargebcelllymphomaabcdlbclacosteffectivenessanalysis
AT pricaa p1731ibrutinibplusrchopversusrchoponlyinyoungpatientswithactivatedbcelllikediffuselargebcelllymphomaabcdlbclacosteffectivenessanalysis

Ejemplares similares